Broker Recommendations

GSK's Zantac settlement should give stock a boost, says Jefferies

By Benjamin Chiou

Date: Thursday 10 Oct 2024

(Sharecast News) - GSK's $2.2bn payment to settle 93% of outstanding Zantac lawsuits in the US was close to the "best case scenario", according to Jefferies, which said the announcement should remove a significant weight on the share price.
The broker reiterated a 'buy' rating and 2,000p target price for the...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page